Alexandra Collingbourne Alexandra Collingbourne

Abselion Launches AAVX and AAV9 Total Capsid Quantification Kits

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering, with the launch of the AAVX Total Capsid Quantification Kit and the AAV9 Total Capsid Quantification Kit.

Read More
Alexandra Collingbourne Alexandra Collingbourne

NATO backs 52North tech for nuclear emergency preparedness programme

A University of Cambridge spin-out whose product can be used to treat radiation sickness following a nuclear attack, has secured further recognition with NATO. Based locally at the Hauser Forum, 52North has been recognised for a second time by the North Atlantic Treaty Organization, which is headquartered in Belgium.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Paragraf closes $55M Series C funding round

Paragraf pioneers graphene-based electronics with standard semiconductor processes, producing magnetic sensors and GMS while developing advanced devices.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Tasty new deal as Xampla goes Bunzi jumping

Cambridge-based materials innovation company, Xampla, has heralded a major commercial advance as Bunzl UK & Ireland adds Huhtamaki’s ‘Taste’ hot food boxes with Morro Coating to its comprehensive range of food service packaging.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Cotton Mouton Diagnostics Disrupts Endotoxin Testing

Cotton Mouton Diagnostics, a cutting-edge UK-based diagnostics technology company, has received a half-a-million-pound investment from CPI Enterprises, the investment arm of CPI, as part of the Innovate UK Catapult Associated Fund.

Read More
Alexandra Collingbourne Alexandra Collingbourne

Qureight analyses of Insilico Medicine’s Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight, a techbio company accelerating drug development using its proprietary deep-learning image biomarkers and clinical data analytics platform, today announced the first results from a collaboration with Insilico Medicine (“Insilico”), a clinical-stage biotechnology company driven by generative AI, focused on rentosertib (ISM001-055), a novel TNIK inhibitor discovered using Insilico's generative AI approach, in development for the treatment of IPF.

Read More